Evidence map›Paper›PMID 37509351›Full record

ArticleCancers2023

SaBrcada: Survival Intervals Prediction for Breast Cancer Patients by Dimension Raising and Age Stratification.

Shih-Huan Lin, Ching-Hsuan Chien, Kai-Po Chang, Min-Fang Lu, Yu-Ting Chen, Yen-Wei Chu

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shih-Huan LinPh.D. Program in Medical Biotechnology, National Chung Hsing University, Taichung 40227, Taiwan.
Ching-Hsuan ChienPh.D. Program in Medical Biotechnology, National Chung Hsing University, Taichung 40227, Taiwan.
Kai-Po ChangDepartment of Pathology, China Medical University Hospital, Taichung 404327, Taiwan.ORCID 0000-0003-1730-9728
Min-Fang LuInstitute of Genomics and Bioinformatics, National Chung Hsing University, Taichung 40227, Taiwan.
Yu-Ting ChenPh.D. Program in Medical Biotechnology, National Chung Hsing University, Taichung 40227, Taiwan.
Yen-Wei ChuPh.D. Program in Medical Biotechnology, National Chung Hsing University, Taichung 40227, Taiwan.ORCID 0000-0002-5525-4011

Funding

China Medical University Hospital DMR-112-074National Chung Hsing University and Changhua Christian Hospital NCHU-CCH 11006National Science and Technology Council, Taiwan 109-2313-B-005-019-, 110-2221-E-005-062-MY3, 110-2320-B-039 -014, 110-2321-B-005-005 and 110-2634-F-005 -006Smart Sustainable New Agriculture Research Center (SMARTer) 110-2634-F-005-006
6 · The paper itself

Abstract

(1) Background: Breast cancer is the second leading cause of cancer death among women. The accurate prediction of survival intervals will help physicians make informed decisions about treatment strategies or the use of palliative care. (2) Methods: Gene expression is predictive and correlates to patient prognosis. To establish a reliable prediction tool, we collected a total of 1187 RNA-seq data points from breast cancer patients (median age 58 years) in Fragments Per Kilobase Million (FPKM) format from the TCGA database. Among them, we selected 144 patients with date of death information to establish the SaBrcada-AD dataset. We first normalized the SaBrcada-AD dataset to TPM to build the survival prediction model SaBrcada. After normalization and dimension raising, we used the differential gene expression data to test eight different deep learning architectures. Considering the effect of age on prognosis, we also performed a stratified random sampling test on all ages between the lower and upper quartiles of patient age, 48 and 69 years; (3) Results: Stratifying by age 61, the performance of SaBrcada built by GoogLeNet was improved to a highest accuracy of 0.798. We also built a free website tool to provide five predicted survival periods: within six months, six months to one year, one to three years, three to five years, or over five years, for clinician reference. (4) Conclusions: We built the prediction model, SaBrcada, and the website tool of the same name for breast cancer survival analysis. Through these models and tools, clinicians will be provided with survival interval information as a basis for formulating precision medicine.

Indexed as

age stratificationbreast cancerdata dimension raisingdeep learningsurvival analysis

Identifiers

PMID37509351
PMCPMC10378351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.